Everyday Health on MSN
There’s a new drug for motion sickness — the first in 40 years
The FDA approved the pill Nereus (tradipitant) as a new treatment for vomiting caused by motion sickness, with fewer side ...
Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration (FDA) ...
Does motion sickness turn you into a green, spewing mess? For plenty of people, the answer is yes. Current remedies may or ...
Tradipitant is a selective human substance P/neurokinin-1 receptor antagonist approved for the prevention of vomiting induced by motion in adults.
Stocktwits on MSN
VNDA stock on track to open at three-year high – FDA clears first new motion sickness drug in decades
Two Phase 3 real-world trials, conducted on boats, showed that NEREUS significantly reduced vomiting compared with placebo.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has ...
Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are ...
FDA approval of Vanda’s Nereus marks a rare and meaningful regulatory milestone, introducing the first new pharmacologic ...
The FDA decision was based on results from three late-stage clinical studies, including two Phase 3 trials conducted in ...
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA ...
Vanda Pharmaceuticals has received FDA approval for Nereus (tradipitant), an oral NK-1 receptor antagonist developed to prevent motion-induced vomiting. The approval makes Nereus the first new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback